A multi-institutional evaluation of carboplatin plus docetaxel combination in elderly patients with advanced gastric cancer

Simple item page
dc.contributor.authorKarabulut, Bülent
dc.contributor.authorÖzdemir, Feyyaz
dc.contributor.authorTunalı, Didem
dc.contributor.buuauthorKurt, Ender
dc.contributor.buuauthorÇubukçu, Erdem
dc.contributor.buuauthorÖlmez, Ömer Fatih
dc.contributor.buuauthorKurt, Meral
dc.contributor.buuauthorAvcı, Nilüfer
dc.contributor.buuauthorEvrensel, Türkkan
dc.contributor.buuauthorManavoǧlu, Osman
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Veterinerlik Fakültesi/Radyasyon Onkolojisi Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0003-1637-910Xtr_TR
dc.contributor.orcid0000-0002-9732-5340tr_TR
dc.contributor.researcheridAAJ-1027-2021tr_TR
dc.contributor.researcheridAAA-3961-2020tr_TR
dc.contributor.scopusid7006207332tr_TR
dc.contributor.scopusid53986153800tr_TR
dc.contributor.scopusid26435400000tr_TR
dc.contributor.scopusid8843050600tr_TR
dc.contributor.scopusid55390409800tr_TR
dc.contributor.scopusid6603942124tr_TR
dc.contributor.scopusid6602587152tr_TR
dc.date.accessioned2023-05-26T09:01:05Z
dc.date.available2023-05-26T09:01:05Z
dc.date.issued2013
dc.description.abstractPurpose: Albeit the majority of gastric cancers occur at advanced age, little is known regarding the optimal systemic treatment of elderly patients with advanced gastric cancer (AGC). Methods: Patients with AGC who were >= 65 years old and were treated with carboplatin (area under the curve/AUG 5, on day 1, every 3 weeks) plus docetaxel (75 mg/m(2), on day 1, every 3 weeks) at 3 institutions were included in this retrospective analysis. The efficacy and the safety data of the regimen were analyzed. Results: A total of 30 patients were enrolled. They received 128 cycles of chemotherapy, with a median of 4 cycles (range 2-8). Complete response (CR) and partial response (PR) were observed in 2 (6.7%) and 10 patients (33.3%), respectively, amounting to an overall objective response rate (ORR) of 40%. Seven patients (23.3%) had disease stabilization (SD), and 11(36.7%) showed disease progression (PD). The most common grade 3-4 toxicity was neutropenia occurring in 19 patients (63.3%). The mean progression-free survival (PFS) was 6.0 +/- 0.5 months (95% CI: 5.0-7.4), and the mean overall survival (OS) 12.0 +/- 1.0 months (95% CI: 9.2-12.1). Conclusion: Carboplatin plus docetaxel seems to be an active and well-tolerated regimen, representing a valuable alternative to cisplatin- and/or fluoropyrimidine-containing regimens for the treatment of elderly patients with AGC.en_US
dc.identifier.citationKurt, E. vd. (2013). “A multi-institutional evaluation of carboplatin plus docetaxel combination in elderly patients with advanced gastric cancer”. Journal of BUON, 18(1), 147-153.en_US
dc.identifier.endpage153tr_TR
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue1tr_TR
dc.identifier.pubmed23613400tr_TR
dc.identifier.scopus2-s2.0-84879020596tr_TR
dc.identifier.startpage147tr_TR
dc.identifier.urihttp://hdl.handle.net/11452/32810
dc.identifier.volume18tr_TR
dc.identifier.wos000322750600018tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.collaborationYurt içitr_TR
dc.relation.journalJournal of BUONen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOncologyen_US
dc.subjectCarboplatinen_US
dc.subjectDocetaxelen_US
dc.subjectElderlyen_US
dc.subjectGastric canceren_US
dc.subjectPhase-II trialen_US
dc.subject1st-line chemotherapyen_US
dc.subjectSystemic treatmenten_US
dc.subjectRAndomized-trialen_US
dc.subjectCisplatinen_US
dc.subjectOxaliplatinen_US
dc.subjectFluorouracilen_US
dc.subjectAdenocarcinomaen_US
dc.subjectPaclitaxelen_US
dc.subjectOlderen_US
dc.subject.emtreeCarboplatinen_US
dc.subject.emtreeDocetaxelen_US
dc.subject.emtreeAdvanced canceren_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeAnemiaen_US
dc.subject.emtreeAnorexiaen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeCancer combination chemotherapyen_US
dc.subject.emtreeCancer survivalen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeDisease courseen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeDrug responseen_US
dc.subject.emtreeDrug safetyen_US
dc.subject.emtreeDrug tolerabilityen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeGeriatric patienten_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMucosa inflammationen_US
dc.subject.emtreeMultiple cycle treatmenten_US
dc.subject.emtreeNeutropeniaen_US
dc.subject.emtreeOverall survivalen_US
dc.subject.emtreePost treatment survivalen_US
dc.subject.emtreeProgression free survivalen_US
dc.subject.emtreeRetrospective studyen_US
dc.subject.emtreeStomach canceren_US
dc.subject.emtreeStomatitisen_US
dc.subject.emtreeSurvival timeen_US
dc.subject.emtreeThrombocytopeniaen_US
dc.subject.meshAdenocarcinomaen_US
dc.subject.meshAge factorsen_US
dc.subject.meshAgeden_US
dc.subject.meshAntineoplastic combined chemotherapy protocolsen_US
dc.subject.meshCarboplatinen_US
dc.subject.meshDisease-free survivalen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshKaplan-meier estimateen_US
dc.subject.meshMaleen_US
dc.subject.meshRetrospective studiesen_US
dc.subject.meshStomach neoplasmsen_US
dc.subject.meshTaxoidsen_US
dc.subject.meshTime factorsen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.meshTurkeyen_US
dc.subject.scopusRamucirumab; Rivoceranib; Lineen_US
dc.subject.wosOncologyen_US
dc.titleA multi-institutional evaluation of carboplatin plus docetaxel combination in elderly patients with advanced gastric canceren_US
dc.typeArticle

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus